Organization type


  • Foundation

Early phases


  • Biomarker identification
  • Target validation – Hypothesis verification

Screening


  • Assay development
    • In vitro screening models
    • In vivo screening models

Optimization phases


  • In vitro cellular and organotypic 3D models (including assay/model development and testing)
  • In vivo animal models (including assay/model development and testing)
  • Preclinical phase (including assay/model development and testing)(non-regulatory and regulatory)
    • ADME / DMPK
    • Safety
    • Toxicology

Functional areas


  • Artificial intelligence
  • Molecular and cellular biology
    • Cell line generation
    • Flow cytometry
    • qPCR

Terapeutic areas


  • Autoimmunity / Inflammation
  • Blood and lymphatic system
  • Cardiovascular

Additional activities


  • Government initiatives supporting drug and research collaborations